Dr Conall Watson
ERGO senior research fellow in vaccine epidemiology
- Consultant in Health Protection
- Project lead for Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED)
Conall is an infectious disease epidemiologist in the Epidemic Diseases Research Group, Oxford, and a consultant in health protection in Public Health England’s South East Centre.
His research interests are around emerging diseases which have the potential to be prevented through vaccination, and evidence-informed communicable disease control more broadly. During the 2014-2015 Ebola emergency, as part of a World Health Organization-led partnership, he jointly designed a novel “ring-vaccination” cluster randomised trial of the rVSV-ZEBOV Ebola vaccine. This demonstrated high efficacy in Guinea and led to wider deployment of the vaccine in West Africa and more recently in the Democratic Republic of the Congo.
Conall leads the Oxford component of a multi-institution NIHR project called VEEPED (Vaccine Efficacy Evaluation for Priority Emerging Diseases) which applies mathematical modelling and infectious disease epidemiology for the design of potential vaccine efficacy studies for emerging diseases. Conall is a member of the WHO R&D Blueprint for epidemic preparedness working group on vaccine trial designs.
Other interests include influenza control, typhoid fever control and serological surveillance of infectious diseases.
Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji
Henderson AD. et al, (2021), Nature Communications, 12
Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.
Manoharan L. et al, (2021), Trials, 22
Electronic data management for vaccine trials in low resource settings: Upgrades, scalability and impact of ODK
Marks M. et al, (2021)
Influenza in carehome residents: applying a conceptual framework to describe barriers to the implementation of guidance on treatment and prophylaxis
Phipps E. et al, (2020), Journal of Public Health, 42, 602 - 609
Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji.
Henderson AD. et al, (2020), eLife, 9